Insider trade

Spruce Biosciences (SPRB): Director exercised options on 1,250 units

Douglas Kirk Ways, Director at Spruce Biosciences, reported an option exercise of 1,250 units.

1,250
Derivative units
Traded
Dec 11, 2025
Filed
Jan 21, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 15, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 15, 2025, Bali Muralidhar, Ph.D. notified Spruce Biosciences, Inc. (the “Company”) of his resignation as a member of the Company’s board of directors (the “Board”) and as a member of the compensation committee of the Board, effective immediately.”
  2. Nov 10, 2025Company filing · Form 8-K · ResultsReported its results
  3. Dec 11, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 11, 2025, Tiba Aynechi, Ph.D. notified Spruce Biosciences, Inc. (the “Company”) of her resignation as a member of the board of directors (the “Board”) of the Company and as the Chair of the Compensation Committee of the Board (the “Compensation Committee”), effective immediately.”
  4. Dec 11, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 11, 2025, the board of directors (the “Board”) of Spruce Biosciences, Inc. (the “Company”) appointed Keli Walbert to the Board, effective immediately.”

What came next

  1. Jan 7, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 3 more items)
  2. Mar 9, 2026Company filing · Form 8-K · Material agreement, Agreement endedChanged a top executive or board member, and signed an important agreement (and 2 more items)“On March 9, 2026, the Company announced the appointment of Corwin Dale Hooks as the Company’s Chief Commercial Officer, effective March 9, 2026. Mr. Hooks, age 60, previously served as Chief Commercial Officer of Applied Therapeutics, Inc. from April 2024 until February 2026.”
  3. Mar 16, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Spruce Biosciences

OQRO holds no insider, Congress, fund or contract record for Spruce Biosciences dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SPRB page.

How this filing works

Explore the data

Common questions

Which Spruce Biosciences (SPRB) insider traded, and how much?

Douglas Kirk Ways, Director at Spruce Biosciences, reported an option exercise of 1,250 units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Dec 11, 2025. Filed: Jan 21, 2026. That is 41 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean SPRB stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Spruce Biosciences

Everything OQRO holds on this company is on its SPRB page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data